Research Analysts Set Expectations for Kamada Q1 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Kamada in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Fein expects that the biotechnology company will earn $0.07 per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.

Kamada Price Performance

KMDA stock opened at $7.41 on Friday. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15. The company has a 50-day moving average of $7.10 and a two-hundred day moving average of $6.15. The stock has a market capitalization of $425.93 million, a price-to-earnings ratio of 26.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99.

Kamada Announces Dividend

The company also recently declared a dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Investors Weigh In On Kamada

A number of hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of Kamada in the fourth quarter valued at about $67,000. Public Employees Retirement System of Ohio bought a new stake in shares of Kamada in the third quarter valued at about $77,000. Plato Investment Management Ltd bought a new stake in shares of Kamada in the third quarter valued at about $117,000. NewEdge Advisors LLC lifted its stake in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the period. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.